|
Aug 15
|
Inovio Pharmaceuticals Second Quarter 2025 Earnings: US$0.61 loss per share (vs US$1.19 loss in 2Q 2024)
|
|
Aug 13
|
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
|
|
Aug 12
|
Inovio: Q2 Earnings Snapshot
|
|
Aug 12
|
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
|
|
Aug 11
|
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 11
|
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
|
|
Aug 11
|
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
|
|
Aug 7
|
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
|
|
Aug 5
|
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Aug 4
|
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
|
|
Jul 2
|
INOVIO Announces Proposed Public Offering
|
|
Jul 1
|
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
|
|
Jun 19
|
Inovio Pharmaceuticals (NASDAQ:INO) Will Have To Spend Its Cash Wisely
|
|
Apr 30
|
INOVIO to Present at Upcoming Scientific and Investor Conferences
|
|
Apr 29
|
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
|
|
Mar 13
|
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
|
|
Mar 12
|
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
|
|
Feb 12
|
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
|
|
Feb 12
|
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
|
|
Feb 10
|
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
|